Search
Rescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Categories: Agents Acting on the Renin-Angiotensin SystemAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals. … [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]
Synonyms: 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-, 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamideArdeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnIts molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223] … Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS.
Pegilodecakin
go.drugbank.com/drugs/DB15162InvestigationalPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small
Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATEDVaricella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalfirst line therapy[L1038]. … First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as
Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein EAceclidine
go.drugbank.com/drugs/DB13262Approved[A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768] … [A274273] It has also been studied in the treatment of presbyopia, a common age-related vision loss where the crystalline lens hardens and loses elasticity, impairing near vision.